ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GC Biopharma, GlaxoSmithKline and BioNTech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

GC Biopharma×GlaxoSmithKline×BioNTech×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GC BiopharmaGlaxoSmithKlineBioNTech
studies on the registry794,198125
open to participants now713533
phase 3 studies under way4769
reach primary completion within a year56611
programswith a study of their own in two years788+17 named only24

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGC BiopharmaGlaxoSmithKlineBioNTech
Phase 100%

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%

BioNTech: 4 of its 24 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%
Phase 2

GC Biopharma: 4 of its 7 programs at phase 2

  1. GC4006Aphase 2
  2. gc1134aphase 2
  3. GC3111Bphase 2
  4. hm15421phase 2
57%

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%
67%
Phase 3

GC Biopharma: 3 of its 7 programs at phase 3

  1. MG1111phase 3
  2. vaccination of GC3114Bphase 3
  3. idursulfase betaphase 3
43%

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%

BioNTech: 3 of its 24 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%
Approved, new studies00%

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

BioNTech: 1 of its 24 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GC Biopharma2 readouts · 1 phase 3······

GC Biopharma, May ’27: 1 program whose next study reaches primary completion

  1. GC4006Aphase 2 · May 0 · NCT07728396
··

GC Biopharma, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. MG1111phase 3 · Aug 0 · NCT07054099
··
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GC Biopharma

New programs 1

Reached a new phase 1

  • GC4006Aphase 2 · Oct 21 · COVID-19

Study stopped 0

None

Primary completion later 0

None

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

BioNTech

New programs 3

  • BNT3211phase 2 · first study · Nov 16
  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionGC BiopharmaGlaxoSmithKlineBioNTech
Influenza, Humanall three · compare here

GC Biopharma in Influenza, Human: 1 program

  1. vaccination of GC3114Bphase 3

Their studies: GC Biopharma’s studies of Influenza, Human in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

BioNTech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. pumitamigphase 3
  2. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasms2 of 3 · compare here–

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

BioNTech in Breast Neoplasms: 3 programs

  1. pumitamigphase 3
  2. trastuzumab pamirtecanphase 3
  3. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Breast Neoplasms in search

Colorectal Neoplasms2 of 3 · compare here–
Prostatic Neoplasms2 of 3 · compare here–

BioNTech in Prostatic Neoplasms: 1 program

  1. Elfetabart Drozuntecanphase 3

Their studies: BioNTech’s studies of Prostatic Neoplasms in search

Acquired Immunodeficiency Syndrome2 of 3 · compare here–

GlaxoSmithKline in Acquired Immunodeficiency Syndrome: 3 programs

  1. cabotegravirapproved, new study
  2. Dolutegravirapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Acquired Immunodeficiency Syndrome in search

BioNTech in Acquired Immunodeficiency Syndrome: 1 program

  1. BNT168phase 1

Their studies: BioNTech’s studies of Acquired Immunodeficiency Syndrome in search

Small Cell Lung Carcinoma2 of 3 · compare here–

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

BioNTech in Small Cell Lung Carcinoma: 2 programs

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3

Their studies: BioNTech’s studies of Small Cell Lung Carcinoma in search

Diphtheria2 of 3 · compare here

GC Biopharma in Diphtheria: 1 program

  1. GC3111Bphase 2

Their studies: GC Biopharma’s studies of Diphtheria in search

GlaxoSmithKline in Diphtheria: 2 programs

  1. Pentetic Acidphase 3
  2. dTpa vaccinephase 3

Their studies: GlaxoSmithKline’s studies of Diphtheria in search

–
Endometrial Neoplasms2 of 3 · compare here–

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

BioNTech in Endometrial Neoplasms: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Endometrial Neoplasms in search

Carcinoma, Hepatocellular2 of 3 · compare here–

GlaxoSmithKline in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: GlaxoSmithKline’s studies of Carcinoma, Hepatocellular in search

BioNTech in Carcinoma, Hepatocellular: 1 program

  1. pumitamigphase 3

Their studies: BioNTech’s studies of Carcinoma, Hepatocellular in search

COVID-192 of 3 · compare here

GC Biopharma in COVID-19: 1 program

  1. GC4006Aphase 2

Their studies: GC Biopharma’s studies of COVID-19 in search

–

BioNTech in COVID-19: 1 program

  1. BNT162 Vaccineapproved, new study

Their studies: BioNTech’s studies of COVID-19 in search

Neoplasm Metastasis2 of 3 · compare here–

GlaxoSmithKline in Neoplasm Metastasis: 1 program

  1. neladalkibphase 3

Their studies: GlaxoSmithKline’s studies of Neoplasm Metastasis in search

BioNTech in Neoplasm Metastasis: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Neoplasm Metastasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: GC Biopharma 0 of 7 · GlaxoSmithKline 65 of 88 · BioNTech 11 of 24 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17).